NKTR
Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company\'s research and development activities involve small-molecule drugs, and peptides.
Nektar Therapeutics (NKTR) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D). The rating has held at C for 9 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (2.9) | D+ (1.8) | C+ (2.6) | D (1.2) | C+ (2.6) | C (2.2) |
| 2026-11-06 | B- (2.9) | D+ (1.8) | C+ (2.6) | D- (1.1) | C+ (2.7) | C (2.2) |
| 2026-10-30 | B- (2.9) | D+ (1.8) | C+ (2.7) | D+ (1.7) | C+ (2.7) | C (2.3) |
| 2026-10-23 | B- (2.9) | D+ (1.8) | C+ (2.7) | D (1.5) | C+ (2.6) | C (2.3) |
| 2026-10-16 | B- (2.9) | D+ (1.8) | C+ (2.7) | C- (1.9) | C+ (2.6) | C (2.4) |